Fairvalue-Calculator Fairvalue-Calculator
EN DE

Next Biomedical Co (389650) Fair Value & Analysis

Healthcare · KR · Market cap 347B KRW

Price41,900 KRW
Fair Value17,758 KRW
Upside-57.6%
Quality95/100
Evidence: Low Range 13,319 KRW – 22,198 KRW

Fair value as of: Jun 24, 2026

Analysis

Next Biomedical Co (389650) currently trades at 41,900 KRW, while our model-based Fair Value estimate is 17,758 KRW — implying the stock looks roughly 57.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Next Biomedical Co.,Ltd. engages in the research and development, production, and development of therapeutics, drug delivery system and drug-medical device products in South Korea. It offers hemostatic material for endoscope; and microspheres for vascular embolization. The company was founded in 2014 and is based in Incheon, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Next Biomedical Co (389650) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 17,758 KRW versus a price of 41,900 KRW — about −58% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 389650?
Our 21-model fair value for Next Biomedical Co is 17,758 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 41,900 KRW.
What is the quality score of 389650?
Next Biomedical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.